Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 111

1.

Reducing hippocampal extracellular matrix reverses early memory deficits in a mouse model of Alzheimer's disease.

Végh MJ, Heldring CM, Kamphuis W, Hijazi S, Timmerman AJ, Li KW, van Nierop P, Mansvelder HD, Hol EM, Smit AB, van Kesteren RE.

Acta Neuropathol Commun. 2014 Jun 29;2:76. doi: 10.1186/s40478-014-0076-z.

2.

Hippocampal administration of chondroitinase ABC increases plaque-adjacent synaptic marker and diminishes amyloid burden in aged APPswe/PS1dE9 mice.

Howell MD, Bailey LA, Cozart MA, Gannon BM, Gottschall PE.

Acta Neuropathol Commun. 2015 Sep 4;3:54. doi: 10.1186/s40478-015-0233-z.

3.

Hippocampal spatial memory impairments caused by the familial Alzheimer's disease-linked presenilin 1 M146V mutation.

Sun X, Beglopoulos V, Mattson MP, Shen J.

Neurodegener Dis. 2005;2(1):6-15.

PMID:
16908998
4.

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease.

McClean PL, Hölscher C.

Neuropharmacology. 2014 Jan;76 Pt A:57-67. doi: 10.1016/j.neuropharm.2013.08.005. Epub 2013 Aug 21.

PMID:
23973293
5.

The Transient Receptor Potential Melastatin 2 (TRPM2) Channel Contributes to β-Amyloid Oligomer-Related Neurotoxicity and Memory Impairment.

Ostapchenko VG, Chen M, Guzman MS, Xie YF, Lavine N, Fan J, Beraldo FH, Martyn AC, Belrose JC, Mori Y, MacDonald JF, Prado VF, Prado MA, Jackson MF.

J Neurosci. 2015 Nov 11;35(45):15157-69. doi: 10.1523/JNEUROSCI.4081-14.2015.

6.

Soluble Aβ levels correlate with cognitive deficits in the 12-month-old APPswe/PS1dE9 mouse model of Alzheimer's disease.

Zhang W, Hao J, Liu R, Zhang Z, Lei G, Su C, Miao J, Li Z.

Behav Brain Res. 2011 Sep 23;222(2):342-50. doi: 10.1016/j.bbr.2011.03.072. Epub 2011 Apr 14.

PMID:
21513747
7.

Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice.

Trinchese F, Liu S, Battaglia F, Walter S, Mathews PM, Arancio O.

Ann Neurol. 2004 Jun;55(6):801-14.

PMID:
15174014
8.

Age-dependent increase in lysosome-associated membrane protein 1 and early-onset behavioral deficits in APPSL transgenic mouse model of Alzheimer's disease.

Hashimoto T, Ogino K, Shin RW, Kitamoto T, Kikuchi T, Shimizu N.

Neurosci Lett. 2010 Jan 22;469(2):273-7. doi: 10.1016/j.neulet.2009.12.015. Epub 2009 Dec 16.

PMID:
20025930
9.

Elevation of brain magnesium prevents synaptic loss and reverses cognitive deficits in Alzheimer's disease mouse model.

Li W, Yu J, Liu Y, Huang X, Abumaria N, Zhu Y, Huang X, Xiong W, Ren C, Liu XG, Chui D, Liu G.

Mol Brain. 2014 Sep 13;7:65. doi: 10.1186/s13041-014-0065-y.

10.

Reduced Reelin expression accelerates amyloid-beta plaque formation and tau pathology in transgenic Alzheimer's disease mice.

Kocherhans S, Madhusudan A, Doehner J, Breu KS, Nitsch RM, Fritschy JM, Knuesel I.

J Neurosci. 2010 Jul 7;30(27):9228-40. doi: 10.1523/JNEUROSCI.0418-10.2010.

11.

Conditional inactivation of presenilin 1 prevents amyloid accumulation and temporarily rescues contextual and spatial working memory impairments in amyloid precursor protein transgenic mice.

Saura CA, Chen G, Malkani S, Choi SY, Takahashi RH, Zhang D, Gouras GK, Kirkwood A, Morris RG, Shen J.

J Neurosci. 2005 Jul 20;25(29):6755-64.

12.

Treadmill exercise prevents decline in spatial learning and memory in APP/PS1 transgenic mice through improvement of hippocampal long-term potentiation.

Liu HL, Zhao G, Cai K, Zhao HH, Shi LD.

Behav Brain Res. 2011 Apr 15;218(2):308-14. doi: 10.1016/j.bbr.2010.12.030. Epub 2010 Dec 27.

PMID:
21192984
13.

Cholinergic degeneration is associated with increased plaque deposition and cognitive impairment in APPswe/PS1dE9 mice.

Laursen B, Mørk A, Plath N, Kristiansen U, Bastlund JF.

Behav Brain Res. 2013 Mar 1;240:146-52. doi: 10.1016/j.bbr.2012.11.012. Epub 2012 Nov 22.

PMID:
23178660
14.

Amyloid-beta deposition is associated with decreased hippocampal glucose metabolism and spatial memory impairment in APP/PS1 mice.

Sadowski M, Pankiewicz J, Scholtzova H, Ji Y, Quartermain D, Jensen CH, Duff K, Nixon RA, Gruen RJ, Wisniewski T.

J Neuropathol Exp Neurol. 2004 May;63(5):418-28.

PMID:
15198121
15.

S14G-humanin improves cognitive deficits and reduces amyloid pathology in the middle-aged APPswe/PS1dE9 mice.

Zhang W, Zhang W, Li Z, Hao J, Zhang Z, Liu L, Mao N, Miao J, Zhang L.

Pharmacol Biochem Behav. 2012 Jan;100(3):361-9. doi: 10.1016/j.pbb.2011.09.012. Epub 2011 Oct 2.

PMID:
21993310
16.

Episodic-like memory deficits in the APPswe/PS1dE9 mouse model of Alzheimer's disease: relationships to beta-amyloid deposition and neurotransmitter abnormalities.

Savonenko A, Xu GM, Melnikova T, Morton JL, Gonzales V, Wong MP, Price DL, Tang F, Markowska AL, Borchelt DR.

Neurobiol Dis. 2005 Apr;18(3):602-17.

PMID:
15755686
17.

The involvement of Cdk5 activator p35 in social isolation-triggered onset of early Alzheimer's disease-related cognitive deficit in the transgenic mice.

Hsiao YH, Chen PS, Chen SH, Gean PW.

Neuropsychopharmacology. 2011 Aug;36(9):1848-58. doi: 10.1038/npp.2011.69. Epub 2011 May 4.

18.

Temporal memory deficits in Alzheimer's mouse models: rescue by genetic deletion of BACE1.

Ohno M, Chang L, Tseng W, Oakley H, Citron M, Klein WL, Vassar R, Disterhoft JF.

Eur J Neurosci. 2006 Jan;23(1):251-60.

PMID:
16420434
19.

Transgenic mice with chronic NGF deprivation and Alzheimer's disease-like pathology display hippocampal region-specific impairments in short- and long-term plasticities.

Houeland G, Romani A, Marchetti C, Amato G, Capsoni S, Cattaneo A, Marie H.

J Neurosci. 2010 Sep 29;30(39):13089-94. doi: 10.1523/JNEUROSCI.0457-10.2010.

20.

The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer's disease.

McClean PL, Parthsarathy V, Faivre E, Hölscher C.

J Neurosci. 2011 Apr 27;31(17):6587-94. doi: 10.1523/JNEUROSCI.0529-11.2011.

Supplemental Content

Support Center